Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X about a recent article by Sarah Waliany et al, published in Clinical Cancer Research:
“Update for RET NSCLC describes acquired resistance to selective RET inhibitors.
The ‘RETgistry’ included 109 patients with post-SRI biopsies and showed 14% with secondary RET mutations.
Off target included MET (18%), KRAS (7%), CDKN2A/B (5%).”
Title: Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Authors: Sarah Waliany, Alissa J. Cooper, Stephen V. Liu, Oliver Gautschi, Julia K. Rotow, Katherine Emilie Rhoades Smith, Urs M. Weber, Dae Ho Lee, Herbert H. F. Loong, Jyoti D. Patel, Nathan A. Pennell, Misako Nagasaka, Shetal A. Patel, Daniel S. W. Tan, Benjamin J. Solomon, Tae Min Kim, Georg Pall, Jonathan W. Riess, Lova Sun, Martin Früh, Natalie F. Uy, Shirish Gadgeel, Jamie Feng, Andrew Do, Christina Falcon, Natasha B. Leighl, Christina S. Baik, Gillianne G. Y. Lai, S. Ignatius Ou, Kingsley S. Y. Cheung, Tejas Patil, Aaron S. Mansfield, Daniela Weiler, Beow Y. Yeap, Lori J. Wirth, Justin F. Gainor, Alexander Drilon, Jessica J. Lin
Read the Full Article on Clinical Cancer Research
More posts featuring Stephen V Liu.